A Boceprevir Failure in a Patient Infected with HCV Genotype 1G: Importance and Limitations of Virus Genotyping Prior to HCV Protease-Inhibitor-Based Therapy
Valeria Cento(Rostov State Medical University), Francesca Ceccherini‐Silberstein(University of Cologne), Simona Landonio(ASST Fatebenefratelli Sacco), Carmen Mirabelli(University of Michigan), Velia Chiara Di Maio(University of Rome Tor Vergata), Francesca De Luca(University of Rome Tor Vergata), Valeria Micheli(ASST Fatebenefratelli Sacco), Carlo Federico Perno(Centre International De Reference Chantal Biya), C. Magni(ASST Fatebenefratelli Sacco), Fosca Niero(Luigi Sacco Hospital), Giuliano Rizzardini
Cited by 19
Related Papers
Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B Infection
|New England Journal of Medicine|2022|264
Recommendations for enterovirus diagnostics and characterisation within and beyond Europe
|Journal of Clinical Virology|2018|263
Morphological cell profiling of SARS-CoV-2 infection identifies drug repurposing candidates for COVID-19
|Proceedings of the National Academy of Sciences|2021|199
Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C
|Journal of Hepatology|2018|133
Incidence of Adverse Reactions in HIV Patients Treated With Protease Inhibitors: A Cohort Study
|JAIDS Journal of Acquired Immune Deficiency Syndromes|2000|115